Last reviewed · How we verify

daily intranasal administration of insulin

University of Turku · Phase 3 active Small molecule

daily intranasal administration of insulin is a Insulin Small molecule drug developed by University of Turku. It is currently in Phase 3 development for Type 1 diabetes, Type 2 diabetes.

Insulin is administered intranasally to lower blood glucose levels.

Insulin is administered intranasally to lower blood glucose levels. Used for Type 1 diabetes, Type 2 diabetes.

At a glance

Generic namedaily intranasal administration of insulin
SponsorUniversity of Turku
Drug classInsulin
TargetInsulin receptor
ModalitySmall molecule
Therapeutic areaDiabetes
PhasePhase 3

Mechanism of action

This is achieved by mimicking the natural insulin signaling pathway, promoting glucose uptake in cells and inhibiting glucose production in the liver. The intranasal route allows for direct delivery to the brain, potentially reducing the risk of hypoglycemia compared to traditional subcutaneous insulin administration.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about daily intranasal administration of insulin

What is daily intranasal administration of insulin?

daily intranasal administration of insulin is a Insulin drug developed by University of Turku, indicated for Type 1 diabetes, Type 2 diabetes.

How does daily intranasal administration of insulin work?

Insulin is administered intranasally to lower blood glucose levels.

What is daily intranasal administration of insulin used for?

daily intranasal administration of insulin is indicated for Type 1 diabetes, Type 2 diabetes.

Who makes daily intranasal administration of insulin?

daily intranasal administration of insulin is developed by University of Turku (see full University of Turku pipeline at /company/university-of-turku).

What drug class is daily intranasal administration of insulin in?

daily intranasal administration of insulin belongs to the Insulin class. See all Insulin drugs at /class/insulin.

What development phase is daily intranasal administration of insulin in?

daily intranasal administration of insulin is in Phase 3.

What are the side effects of daily intranasal administration of insulin?

Common side effects of daily intranasal administration of insulin include Hypoglycemia, Nasal congestion, Headache.

What does daily intranasal administration of insulin target?

daily intranasal administration of insulin targets Insulin receptor and is a Insulin.

Related